UT-15: Treatment of pulmonary hypertension, treatment of peripheral vascular disease

Drugs of the Future

Volumn 26, Issue 4, 2001, Pages 364-374

  Sorbera, L A ^a   Rabasseda, X ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

15 AU81; ANTIHYPERTENSIVE AGENT; BERAPROST; ILOPROST; PROSTACYCLIN; UNCLASSIFIED DRUG; UNIPROST;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; LUNG VASCULAR RESISTANCE; MULTICENTER STUDY; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RAT;

EID: 0034948947     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.04.618809     Document Type: Article

References (37)

1. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin
2. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation
3. 2) by layers of the arterial wall: An explanation for the antithrombotic properties of vascular endothelium
4. 2 by cultured human endothelial cells
5. 2 (prostacyclin) by cultured human and bovine endothelial cells
6. Localisation and stimulation of prostacyclin production in vascular cells
7. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system
8. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets
9. Effect of prostacyclin (PGI2) on platelet adhesion to rabbit arterial subendothelium
10. UT-15, a novel prostacyclin analogue, displays potent antiproliferative activity in human pulmonary artery smooth muscle cells
11. Pulmonary vasodilation by airway delivered prostacyclin analogues, UT-15 & pegylated UT-15
12. The effects of 15AU81, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensin systems of anesthetized dogs
13. 15 AU81, a protacyclin analog, potentiates immunosuppression and mitigates renal injury due to cyclosporine
14. 15AU81, a prostacyclin analog, enhances donor specific hepatocytes to prolong the survival of rat heart but not small bowel allografts
15. Radioimmunoassay for the chemical stable prostacyclin analog, 15AU81: A preliminary pharmacokinetics study in the dog
16. The pharmacokinetics and pharmacodynamics of the prostacyclin analog 15AU81 in the anesthetized beagle dog
17. Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure
18. Efficacy and safety of UT-15, a prostacyclin analogue, for primary pulmonary hypertension
19. Efficacy of longterm subcutaneous infusion of UT-15 in primary pulmonary hypertension
20. Long term effects of UT-15 on hemodynamics and exercise tolerance in primary pulmonary hypertension
21. Efficacy and safety of chronic subcutaneous infusion UT-15 in pulmonary arterial hypertension (PAH)
22. Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication
23. Phase 2 trial of a novel prostacyclin analogue, UT-15, in patients with severe intermittent claudication
24. Acute hemodynamic effects of BW15AU in patients with severe congestive heart failure
25. High-performance liquid chromatographic method for determining the enantiomeric purity of a benzindene prostaglandin by a diastereomeric separation
26. Acute hemodynamic effects of 15AU81, a stable epoprostenol analogue, in severe primary pulmonary hypertension